Aug. 3, 2009 - SuperGen Inc., (NASDAQ: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that preliminary results from Phase Ib data of MP-470, its multi-targeted, tyrosine kinase inhibitor and RAD51 suppressor, demonstrated an overall clinical benefit rate of 54 percent when the drug is given in combination with standard of care (SOC) carboplatin containing doublet chemotherapy in patients with small cell lung cancer (SCLC) and neuroendocrine malignancies (NE). The data was presented on August 2, at the International Association for the Study of Lung Cancer (IASLC), 13th World Conference on Lung Cancer in San Francisco, CA.The Phase I dose titration study enrolled four patients with SCLC and nine patients with NE as of February 28, 2009. As measured by the Response Evaluation Criteria in Solid Tumors (RECIST), five of thirteen patients achieved a confirmed partial response and two additional patients demonstrated stable disease greater than twelve weeks for an overall clinical benefit rate of 7/13 patients or 54% (95% CI, 25% - 81%). There were no clinically significant adverse events attributable to the addition of MP-470 to SOC. "We continue to be encouraged by the clinical data resulting from our MP-470 trials and the potential benefit of its addition to standard of care treatment regimens... SuperGen's Press Release -
